Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $78.3 million.

  • Prestige Consumer Healthcare's Cash from Operations rose 2027.32% to $78.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $276.6 million, marking a year-over-year increase of 781.84%. This contributed to the annual value of $251.5 million for FY2025, which is 104.01% up from last year.
  • As of Q4 2025, Prestige Consumer Healthcare's Cash from Operations stood at $78.3 million, which was up 2027.32% from $57.5 million recorded in Q3 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Cash from Operations peaked at $79.0 million during Q2 2025, and registered a low of $48.1 million during Q2 2023.
  • Its 5-year average for Cash from Operations is $63.2 million, with a median of $62.2 million in 2023.
  • The largest annual percentage gain for Prestige Consumer Healthcare's Cash from Operations in the last 5 years was 4424.75% (2025), contrasted with its biggest fall of 1764.18% (2025).
  • Over the past 5 years, Prestige Consumer Healthcare's Cash from Operations (Quarter) stood at $66.3 million in 2021, then dropped by 17.13% to $54.9 million in 2022, then soared by 30.09% to $71.5 million in 2023, then decreased by 8.93% to $65.1 million in 2024, then rose by 20.27% to $78.3 million in 2025.
  • Its Cash from Operations stands at $78.3 million for Q4 2025, versus $57.5 million for Q3 2025 and $79.0 million for Q2 2025.